Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Halia Therapeutics' Ofirnoflast...
Business clinical trial results

Halia Therapeutics' Ofirnoflast Phase 2 Results

Analysis based on 6 articles · First reported May 12, 2026 · Last updated May 12, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive Phase 2 results for ofirnoflast (HT-6184) from Halia Therapeutics could lead to increased investor interest in the company and the broader biotechnology sector, particularly in companies developing treatments for hematologic diseases. The appointment of Win Myint as Chief Medical Officer further strengthens Halia Therapeutics's leadership, potentially boosting confidence in its future clinical development and regulatory success.

Biotechnology Pharmaceuticals
Event Summary

Halia Therapeutics, a clinical-stage biopharmaceutical company, announced positive final Phase 2 results for its drug ofirnoflast (HT-6184) in patients with lower-risk myelodysplastic syndrome (LR-MDS). The data, which will be presented at the European Hematology Association (EHA) 2026 Hybrid Congress, showed a 67% overall hematological improvement rate and durable transfusion independence with a favorable safety profile. Concurrently, Halia Therapeutics appointed Win Myint, an experienced hematologist-oncologist and drug-development executive, as its Chief Medical Officer. Dr. Myint will lead the company's global clinical development, medical affairs, and safety strategy as ofirnoflast (HT-6184) advances toward pivotal trials and the broader pipeline progresses.

Key Actions
100 Halia Therapeutics announced results
85 Halia Therapeutics appointed Win Myint
70 Halia Therapeutics will present data European Hematology Association
Entities Involved
priv
Halia Therapeutics
Halia Therapeutics announced positive final Phase 2 results for its drug ofirnoflast (HT-6184) in lower-risk myelodysplastic syndrome (LR-MDS) and appointed Win Myint as Chief Medical Officer, strengthening its clinical development capabilities.
Importance 100 Sentiment 70
per
Win Myint
Win Myint was appointed Chief Medical Officer of Halia Therapeutics, bringing extensive experience in hematologic malignancies and oncology drug development to lead the company's clinical strategy.
Importance 80 Sentiment 50
ngo
European Hematology Association
The European Hematology Association will host the EHA2026 Hybrid Congress where Halia Therapeutics will present its final Phase 2 data for ofirnoflast (HT-6184).
Importance 20 Sentiment 0
stock
Bristol Myers Squibb
Bristol Myers Squibb is mentioned as the current owner of Oracle Corporation, where Win Myint previously held senior leadership roles.
Importance 5 Sentiment 0
stock
Oracle Corporation
Oracle Corporation is mentioned as a former employer of Win Myint, where he contributed to the development and launch of therapies for myeloid diseases.
Importance 5 Sentiment 0
stock
NextCure
NextCure is mentioned as a former employer of Win Myint, where he served as Chief Medical Officer.
Importance 5 Sentiment 0
stock
NexImmune
NexImmune is mentioned as a former employer of Win Myint, where he served as Chief Medical Officer.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.